The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Expression of Cyclin-Dependent Kinase Inhibitors in Vascular Disease
Open accessAbstract
Abstract —Arterial lesions in cardiovascular diseases are characterized by proliferation and migration of smooth muscle cells as well as deposition of connective tissue matrix. Factors that stimulate vascular smooth muscle cell (VSMC) proliferation are well described; however, the role of proteins that limit intimal hyperplasia is not well understood. To examine the function of Kip/Cip and INK cyclin-dependent kinase inhibitors (CKIs) in vascular diseases, the expression of p27 Kip1 and p16 INK was examined in VSMCs in vitro and in porcine arteries and human atherosclerosis in vivo. Western blot and fluorescence activated cell-sorting analysis demonstrated that levels of p27 Kip1 , but not p16 INK , increased during serum deprivation of primary VSMC cultures and caused G 1 arrest. p27 Kip1 inhibited Cdk2 activity, suggesting that Kip CKIs promote G 1 arrest in VSMCs by binding cyclin E/Cdk2. In porcine arteries, p27 Kip1 , but not p16 INK , was constitutively expressed at low levels. Immediately after balloon injury, cell proliferation increased as p27 Kip1 levels declined. Three weeks after injury, p27 Kip1 was strongly expressed in intimal VSMCs when VSMC proliferation was <2%, suggesting that p27 Kip1 functions as an inhibitor of cell proliferation in injured arteries. In contrast, p16 INK expression was detected only transiently early after injury. CKI expression was examined in 35 human coronary arteries, ranging from normal to advanced atherosclerosis. p27 Kip1 expression was abundant in nonproliferating VSMCs and macrophages within normal (7 of 8) and atherosclerotic (25 of 27) arteries. p21 Cip1 levels were undetectable in normal arteries but were elevated in atherosclerotic (19 of 27) arteries. p16 INK could not be detected in normal or atherosclerotic arteries (0 of 35). Thus, the Kip/Cip and INK CKIs have different temporal patterns of expression in VSMCs in vitro and in injured arteries and atherosclerotic lesions in vivo. In contrast to p16 INK , p27 Kip1 likely contributes to the remodeling process in vascular diseases by the arrest of VSMCs in the G 1 phase of the cell cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“CKIs directly implicated in CDK regulation are p21,(6,7) p27, and p16/p15.(11) Since cell proliferation is a prominent feature of cardiovascular diseases, including atherosclerosis, angiogenesis, and restenosis, we hypothesized that CKIs regulate G1 progression in VSMCs and function as endogenous inhibitors of VSMC pr…”
Backgroundp21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., & Nakayama, K.-I. (1996) · Cell · doi:10.1016/s0092-8674(00)81237-4 · Cited by 1,547
Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L.-H., Broudy, V., Perlmutter, R. M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81239-8 · Cited by 1,457
Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27
Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., & Koff, A. (1996) · Cell · doi:10.1016/s0092-8674(00)81238-6 · Cited by 1,251
Schwartz, R. S., Huber, K. C., Murphy, J. G., Edwards, W. D., Camrud, A. R., Vlietstra, R. E., & Holmes, D. R. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90476-4 · Cited by 1,175
Inhibition of cyclin-dependent kinases by p21.
Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L. H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., & Swindell, E. (1995) · Molecular Biology of the Cell · doi:10.1091/mbc.6.4.387 · Cited by 1,023
The Intima: Soil for Atherosclerosis and Restenosis
Schwartz, S. M., deBlois, D., & O’Brien, E. R. M. (1995) · Circulation Research · doi:10.1161/01.res.77.3.445 · Cited by 971
Gerdes, J., Li, L., Schlueter, C. J., Duchrow, M., Wohlenberg, C., Gerlach, C., Stahmer, I., Kloth, S., Brandt, E., & Flad, H. D. (1991) · PubMed · Cited by 889
Requirement of p27 Kip1 for Restriction Point Control of the Fibroblast Cell Cycle
Coats, S., Flanagan, W. M., Nourse, J., & Roberts, J. M. (1996) · Science · doi:10.1126/science.272.5263.877 · Cited by 679
Signal Transduction by the Platelet-Derived Growth Factor Receptor
Williams, L. T. (1989) · Science · doi:10.1126/science.2538922 · Cited by 635
Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model.
Steele, P. M., Chesebro, J. H., Stanson, A. W., Holmes, D. R., Dewanjee, M. K., Badimon, L., & Fuster, V (1985) · Circulation Research · doi:10.1161/01.res.57.1.105 · Cited by 632
Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1
Luo, Y., Hurwitz, J., & Massagué, J. (1995) · Nature · doi:10.1038/375159a0 · Cited by 549
Cell proliferation in human coronary arteries.
Gordon, D., Reidy, M. A., Benditt, E. P., & Schwartz, S. M. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4600 · Cited by 532
Self-citationKoyama, H., Raines, E. W., Bornfeldt, K. E., Roberts, J. M., & Ross, R. (1996) · Cell · doi:10.1016/s0092-8674(00)81801-2 · Cited by 515
Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury
Ohno, T., Gordon, D., San, H., Pompili, V. J., Imperiale, M. J., Nabel, G. J., & Nabel, E. G. (1994) · Science · doi:10.1126/science.8047883 · Cited by 433
Self-citationNabel, E. G., Shum, L., Pompili, V. J., Yang, Z. Y., San, H., Shu, H. B., Liptay, S., Gold, L., Gordon, D., & Derynck, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10759 · Cited by 380
Self-citationChang, M. W., Barr, E., Lu, M. M., Barton, K., & Leiden, J. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118281 · Cited by 354
Progress in Cell Cycle Research
(1997) · Springer eBooks · doi:10.1007/978-1-4615-5371-7 · Cited by 237
Yang, Z. Y., Simari, R. D., Perkins, N. D., San, H., Gordon, D., Nabel, G. J., & Nabel, E. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7905 · Cited by 232
Self-citationIdentification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1.
Nakanishi, M., Robetorye, R. S., Adami, G. R., Pereira-Smith, O. M., & Smith, J. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07031.x · Cited by 178
Temporally and Spatially Coordinated Expression of Cell Cycle Regulatory Factors After Angioplasty
Wei, G. L., Krasinski, K. L., Kearney, M., Isner, J. M., Walsh, K., & Andrés, V. (1997) · Circulation Research · doi:10.1161/01.res.0000435858.35902.ea · Cited by 131
Transplant arteriosclerosis in a rat aortic model.
Isik, F. F., McDonald, T. O., Ferguson, M. S., Yamanaka, E., & Gordon, D. (1992) · PubMed · Cited by 75
Self-citationp27KIP1, an inhibitor of cyclin-dependent kinases
Koff, A., & Polyák, K. (1995) · Springer eBooks · doi:10.1007/978-1-4615-1809-9_11 · Cited by 51
Cited by
Newby, A. C. (2005) · Physiological Reviews · doi:10.1152/physrev.00048.2003 · Cited by 817
Heme oxygenase-1 protects against vascular constriction and proliferation
Duckers, H. J., Boehm, M., True, A. L., Yet, S.-F., San, H., Park, J. L., Clinton Webb, R., Lee, M.-E., Nabel, G. J., & Nabel, E. G. (2001) · Nature Medicine · doi:10.1038/89068 · Cited by 525
Self-citationMolecular Basis of Restenosis and Drug-Eluting Stents
Costa, M. A., & Simon, D. I. (2005) · Circulation · doi:10.1161/01.cir.0000163587.36485.a7 · Cited by 510
Ylä-Herttuala, S., & Martin, J. F. (2000) · The Lancet · doi:10.1016/s0140-6736(99)04180-x · Cited by 375
Mechanisms of controlled drug release from drug-eluting stents
Acharya, G., & Park, K. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.016 · Cited by 363
Metadata
- Authors
- Tanner, F. C., Yang, Z.-Y., Duckers, E., Gordon, D., Nabel, G. J., & Nabel, E. G.
- Venue
- Circulation Research
- Published
- 1998-02-23
- Volume
- 82
- Issue
- 3
- Pages
- 396-403
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2104576349
- Cited by
- 253
- References
- 32
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.